Efficacy of enrofloxacin in the treatment of naturally occurring acute clinical Escherichia coli mastitis

Journal of Dairy Science

Volumn 93, Issue 5, 2010, Pages 1960-1969

  Suojala, L ^a   Simojoki, H ^a   Mustonen, K ^b   Kaartinen, L ^c   Pyorala S ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Vetcare Ltd   (Finland)

^c NATL VET AND FOOD RES INSTITUTE   (Finland)

Author keywords

Antimicrobial treatment; Bovine mastitis; Enrofloxacin; Escherichia coli

Indexed keywords

ACETYLGLUCOSAMINIDASE; ANTIINFECTIVE AGENT; ENROFLOXACIN; KETOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLONE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BOVINE MASTITIS; CATTLE; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI INFECTION; FEMALE; LACTATION; METABOLISM; MICROBIOLOGY; MILK; RANDOMIZATION; SECRETION; TREATMENT OUTCOME; BOVINAE; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; MASTITIS, BOVINE; SECRETION (PROCESS); VETERINARY;

ACETYLGLUCOSAMINIDASE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATTLE; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; KETOPROFEN; LACTATION; MASTITIS, BOVINE; MILK; RANDOM ALLOCATION; TREATMENT OUTCOME;

BOS; BOVINAE; ESCHERICHIA COLI;

EID: 77952062989     PISSN: 00220302     EISSN: 15253198     Source Type: Journal    
DOI: 10.3168/jds.2009-2462     Document Type: Article

References (34)

1. Banting A., Banting S., Heinonen K., Mustonen K. Efficacy of oral and parenteral ketoprofen in lactating cows with endotoxin-induced acute mastitis. Vet. Rec. 2008, 163:506-509.
2. Bradley A.J., Green M.J. Adaptation of Escherichia coli to the bovine mammary gland. J. Clin. Microbiol. 2001, 39:1845-1849.
3. Burvenich C., Van Merris V., Mehrzad J., Diez-Fraile A., Duchateau L. Severity of E. coli mastitis is mainly determined by cow factors. Vet. Res. 2003, 34:521-564.
4. CDC (Centers for Disease Control and Prevention). 2008. PulseNet Protocols. Accessed Oct. 10, 2008. http://www.cdc.gov/pulsenet/protocols.htm.
5. Cebra C.K., Garry F., Dinsmore R. Naturally occurring acute coliform mastitis in Holstein cattle. J. Vet. Intern. Med. 1996, 10:252-257.
6. CLSI. 2004. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals, informational supplement. CLSI document M31-S1. Clinical Laboratory Standards Institute (CLSI), Wayne, PA.
7. Collignon P., Powers J., Chiller T., Aidara-Kane A., Aarestrup F. World Health Organization ranking of antimicrobials according to their importance in human medicine: A critical step for developing risk management strategies for the use of antimicrobials in food production animals. Clin. Infect. Dis. 2009, 49:132-141.
8. Constable P., Pyörälä S., Smith G. Guidelines for antimicrobial use in cattle. Antimicrobial Use in Animals 2008, 143-160. Blackwell Publishing Ltd., Oxford, UK. L. Guardabassi, L.B. Jensen, H. Kruse (Eds.).
9. Dosogne H., Meyer E., Sturk A., van Loon J., Massart-Leën A., Burvenich C. Effect of enrofloxacin treatment on plasma endotoxin during bovine Escherichia coli mastitis. Inflamm. Res. 2002, 51:201-205.
10. Erskine R.J., Bartlett P., VanLente J., Phipps R. Efficacy of systemic ceftiofur as a therapy for severe clinical mastitis in dairy cattle. J. Dairy Sci. 2002, 85:2571-2575.
11. Fang W., Pyörälä S. Mastitis-causing Escherichia coli: Serum sensitivity and susceptibility to selected antibacterials in milk. J. Dairy Sci. 1996, 79:76-82.
12. FINRES-Vet. 2007. FINRES-Vet 2005-2006: Finnish veterinary antimicrobial resistance monitoring and consumption of antimicrobial agents. Evira Publications 22/2007. Accessed Jan. 28, 2009. http://www.evira.fi/uploads/WebShopFiles/1198141211941.pdf.
13. Golodetz C.L., White M.E. Prognosis for cows with severe clinical coliform mastitis. Vet. Rec. 1983, 112:402-403.
14. Hill A.W. Progressive pathology of severe Escherichia coli mastitis in dairy cows. Res. Vet. Sci. 1984, 37:179-187.
15. Hoeben D., Dosogne H., Heynman R., Burvenich C. Effect of antibiotics on the phagocytotic and respiratory burst activity of bovine granulocytes. Eur. J. Pharmacol. 1997, 332:289-297.
16. Hogan J., Gonzales R., Harmon R., Nickerson S., Oliver S., Pankey J., Smith K. Laboratory Handbook on Bovine Mastitis 1999, National Mastitis Council, Madison, WI.
17. IDF. 1999. Suggested interpretation of mastitis terminology. Smith, K., coordinator. Bulletin no. 338:3-26. International Dairy Federation, Brussels, Belgium.
18. Jones G.F., Ward G.E. Evaluation of systemic administration of gentamicin for treatment of coliform mastitis in cows. J. Am. Vet. Med. Assoc. 1990, 197:731-735.
19. Kaartinen L., Salonen M., Älli L., Pyörälä S. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. J. Vet. Pharmacol. Ther. 1995, 18:357-362.
20. Katholm J., Andersen P. Severe coliform mastitis in practice: Efficacy of the therapy regimen not including antibiotics. Proc. XX World Buiatrics Congress 1998, 261-264.
21. Lehtolainen T., Shwimmer A., Shpigel N., Honkanen-Buzalski T., Pyörälä S. In vitro antimicrobial susceptibility of Escherichia coli isolates originating from clinical mastitis in Finland and Israel. J. Dairy Sci. 2003, 86:3927-3932.
22. Lepper P.M., Held T., Schneider E., Bölke E., Gerlach H., Trautmann M. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med. 2002, 28:824-833.
23. Lohuis J.A., Van Leeuwen W., Verheijden J., Brand A., Van Miert A. Flunixin meglumine and flurbiprofen in cows with experimental Escherichia coli mastitis. Vet. Rec. 1989, 124:305-308.
24. Mattila T., Sandholm M. Milk plasmin, N-acetyl-beta-d-glucosaminidase, and antitrypsin as determinants of bacterial replication rates in whey. J. Dairy Sci. 1986, 69:670-675.
25. Mattila T., Syväjärvi J., Sandholm M. Bacterial growth in whey from mastic and nonmastitic quarters. Am. J. Vet. Res. 1984, 45:1-3.
26. McDougall S., Bryan M., Tiddy R. Effect of treatment with the nonsteroidal anti-inflammatory meloxicam on milk production, somatic cell count, probability of re-treatment, and culling of dairy cows with mild clinical mastitis. J. Dairy Sci. 2009, 92:4421-4431.
27. Poutrel B., Stegemann M., Roy O., Pothier F., Tilt N., Payne-Johnson M. Evaluation of the efficacy of systemic danofloxacin in the treatment of induced acute Escherichia coli bovine mastitis. J. Dairy Res. 2008, 75:310-318.
28. Pyörälä S., Kaartinen L., Käck H., Rainio V. Efficacy of two therapy regimens for treatment of experimentally induced Escherichia coli mastitis in cows. J. Dairy Sci. 1994, 77:453-461.
29. Pyörälä S., Pyörälä E. Accuracy of methods using somatic cell count and milk N-acetyl-β-D-glucosaminidase activity in milk to assess the bacteriological cure of bovine clinical mastitis. J. Dairy Sci. 1997, 80:2820-2825.
30. Pyörälä S.H., Pyörälä E.O. Efficacy of parenteral administration of three antimicrobial agents in treatment of clinical mastitis in lactating cows: 487 cases (1989-1995). J. Am. Vet. Med. Assoc. 1998, 212:407-412.
31. Rantala M., Kaartinen L., Välimäki E., Stryrman M., Hiekkaranta M., Niemi A., Saari L., Pyörälä S. Efficacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. J. Vet. Pharmacol. Ther. 2002, 25:251-258.
32. Shpigel N.Y., Chen R., Winkler M., Saran A., Ziv G., Longo F. The anti-inflammatory ketoprofen in the treatment of field cases of bovine mastitis. Res. Vet. Sci. 1994, 56:62-68.
33. Vandeputte-Van Messom G., Burvenich C., Roets E., Massart-Leën A.-M., Heyneman R., Kremer W., Brand A. Classification of newly calved cows into moderate and severe responders to experimentally induced Escherichia coli mastitis. J. Dairy Res. 1993, 60:19-29.
34. Wenz J.R., Barrington G., Garry F., McSweeney K., Dinsmore R., Goodell G., Callan R. Bacteremia associated with naturally occurring acute coliform mastitis in dairy cows. J. Am. Vet. Med. Assoc. 2001, 219:976-981.